**Appendix Table C3. KQ1: Darbepoetin versus epoetin, study characteristics, Part II**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **study author** | **n randomized** | **cancer details** | **cancer category** | **therapy** | **Hb eligibility criteria** | **Hb baseline Darb arm [mean g/dl (SD)]** | **Hb baseline EPO arm [mean g/dl (SD)]** | **Hb category*****Target*** | **Age Darb arm [mean (SD)] if not stated otherwise** | **Age EPO arm [mean (SD)] if not stated otherwise** | **age category (children , adults, elderly (>65)** |
| **Glaspy 2002, Part A** | 269 | Breast, GI, lung, other | solid | chemotherapy | Hb ≤ 11 g/dL  | 9.91 (SD 0.94) | 10.02 (SD 0.88) | > 12*14 for women**15 for men* | 61.9 (SD 11.9) | 57.8 (SD 14.5) | adults |
| **Glaspy 2006** | 1220 | lung, breast, GI, gyne, lymphoproliferative (7.5%), other cancers | solid or hematological | chemotherapy, some (42%) platinum-based | Hb ≤11 g/dL  | 10.18 (SD 0.90) | 10.21 (SD 0.89) | > 12*13* | 63.2 (SD 12.4) | 63.7 (SD 11.6) | adults |
| **Schwartzberg 2004, a-c** | 318 | a: breast cancer, b: lung cancer (stage IIIb, IV), c: gynecological cancers | solid | chemotherapy, some platinum-based (41%) | Hb ≤ 11 g/dL  | 10.4 (SD 0.8) | 10.4 (SD 0.8) | > 12*13* | 58.7 (SD 11.5) | 61.7 (SD 12.1) | adults |
| **Waltzman 2005** | 358 | lung, breast | solid | chemotherapy, some platinum-based (40.5%) | Hb ≤ 11 g/dL  | 10.07 (SD 0.79) | 10.16 (SD 0.75) | > 12*13* | 63.4 (SD 11.8) | 62.1 (SD 11.8) | adults |
| **Kotsori 2006** | 110 | Non hematological tumors | solid | unclear | Hb ≤ 11 g/dL | 10.26 (SD 0.81) | 10.11(SD 0.94) | NR | NR | NR | NR |